Do academic or investigator-sponsored gene therapy trials need their own insurance?

Yes, and the structure is usually a coordination of layers rather than a single policy. An academic medical center running an investigator-sponsored gene-therapy trial typically relies on its self-insurance trust as the primary coverage, which covers the AMC investigator and AMC sites. But multi-center trials with external sites - other institutions, community hospitals - fall outside the trust scope, and those need standalone clinical trial liability with the investigator-sponsor as named insured.

The gene-therapy long tail complicates this. Because FDA expects long-term follow-up of up to 15 years and the coverage is claims-made, the IND holder has to think about how the delayed-injury window is covered after the trial ends, including whether a tail is purchased and how the academic self-insurance treats late-reported claims. Industry-funded academic trials add a sponsor backstop indemnity layer on top.

Coordinating these layers - academic self-insurance, standalone clinical trial liability for external sites, any industry backstop, and the long-tail tail - is the standard placement for an investigator-sponsored gene-therapy trial, and it is worth structuring before enrollment rather than after.